Exposing KRAS G12C: Not Your Usual Suspect in NSCLC
Overview
KRAS G12C Is a Unique Suspect in NSCLC That Challenges Our Conventional Thinking
KRAS G12C is different from other oncogenic drivers. Although long considered undruggable, novel approaches have led to the development of targeted therapies, which are currently approved only as monotherapy in the second line (2L).1-5 KRAS G12C is associated with poor prognosis in lung cancer.6 Of patients who receive first line (1L) treatment, only 38% patients advance to 2L.7
These educational resources provide an understanding of how KRAS G12C is different from other oncogenic drivers and other KRAS variants, the role of the mutated KRAS G12C in tumor formation and survival, and how these insights can be leveraged to care for patients with KRAS G12C–mutant non-small cell lung cancer (NSCLC).
These educational resources provide an understanding of how KRAS G12C is different from other oncogenic drivers and other KRAS variants, the role of the mutated KRAS G12C in tumor formation and survival, and how these insights can be leveraged to care for patients with KRAS G12C–mutant non-small cell lung cancer (NSCLC).
Find out what makes KRAS G12C unique
Abbreviations
1L = first line; 2L = second line; KRAS = Kirsten rat sarcoma; NSCLC = non-small cell lung cancer.
References
- Singhal A, et al. Targeting KRAS in cancer. Nat Med. 2024;30(4):969-983.
- Lim TKH, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer. 2023;184:107293.
- Ferreira A, et al. Crucial role of oncogenic KRAS mutations in apoptosis and autophagy regulation: therapeutic implications. Cells. 2022;11(14):2183.
- Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548-51.
- Cheema PK, et al. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Curr Oncol. 2023;30(7):6473-6496.
- Lee JK, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6(1):91.
- Sheffield K, et al. Real-world outcomes with IO and chemo-IO demonstrate unmet need for 1L KRAS G12C-mutant advanced NSCLC in the US. Presented at: IASCL 2025 World Conference on Lung Cancer (WCLC); September 6-9, 2025; Barcelona, Spain. Poster 1615.
VV-MED-175543
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice